LCTX
HealthcareLineage Cell Therapeutics, Inc.
$1.69
+$0.05 (+3.05%)
Jan 5, 2026
Price History (1Y)
Analysis
Lineage Cell Therapeutics, Inc. (LCTX) is a biotechnology company in the healthcare sector with a market capitalization of $389.25M and 70 employees. The company operates within the biotechnology industry. The financial health of LCTX is concerning. The company reported a net income of -$67,657,000 and an EBITDA of -$19,677,000 over the trailing twelve months. This resulted in negative operating margin of -102.9% and profit margin of 0.0%. Additionally, the return on equity (ROE) was -157.8%, and the return on assets (ROA) was -13.7%. The company's balance sheet shows a cash position of $40.49M and debt of $2.62M, resulting in a debt to equity ratio of 12.60. The valuation context of LCTX is marked by negative earnings growth, as indicated by the forward P/E ratio of -29.82. The price to sales ratio was 35.99, and the price to book ratio was 17.60. The company's revenue growth over the past year was -2.6%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Visit website →Key Statistics
- Market Cap
- $389.25M
- P/E Ratio
- N/A
- 52-Week High
- $2.09
- 52-Week Low
- $0.37
- Avg Volume
- 1.81M
- Beta
- 1.75
Company Info
- Industry
- Biotechnology
- Exchange
- ASE
- Country
- United States
- Employees
- 70